Product · #7 of 27 · multi-symptom
Nature's Bounty Optimal Solutions Advanced Menopause Relief
Tablet from Nature's Bounty, made by Nestlé Health Science. Daily serving: 1 tablet with a meal.
Last updated · Price and ratings checked Nov 19, 2026
In short: Nature's Bounty Optimal Solutions Advanced Menopause Relief scores 56.7/100 in our ranking (#7 of 27). It costs $0.67 a day at the regular price. Evidence: ERr 731 4 mg + affron saffron (mood); best ingredient grade C (ERr 731 rhapontic rhubarb). No NSF registry listing was confirmed.
Pros
- Low cost: $0.67 a day at the label dose.
- Evidence: ERr 731 4 mg + affron saffron (mood).
Cons
- No NSF registry listing confirmed.
Flags
None found
Score breakdown
Full label: what's in it
| Ingredient (as labeled) | Per day | Evidence page |
|---|---|---|
| Rhapontic (Siberian) rhubarb extract ERr 731 (2.2 mg rhaponticin + 1 mg desoxyrhaponticin) | 4 mg | ERr 731 rhapontic rhubarb C |
| Saffron extract affron (Crocus sativus stigma) | 28 mg | Saffron (affron) C |
Same ERr 731 active and dose as Estroven Complete, plus affron saffron. U.S. News lists this product as containing genistein; the official label says otherwise.
Evidence
Our evidence score: 29/40, because: ERr 731 4 mg + affron saffron (mood).
Product-level research: we found no published trial of this exact product, so its evidence comes from studies of its ingredients.
Ingredient evidence
- ERr 731 rhapontic rhubarb C (4 mg here)
ERr 731 is a rhapontic rhubarb root extract (the active in Estroven Complete) studied in perimenopausal women for occasional hot flashes and related symptoms*. The placebo-controlled trials come from one research group. The Menopause Society 2023: Not recommended (Level II) – placebo-arm retention only 12.7% in key RCT; open-label study. - Saffron (affron) C (28 mg here)
Saffron extract has been studied for occasional low mood and feelings of anxiousness in perimenopause*. In the largest menopause trial it did not reduce hot flashes. The Menopause Society 2023: Not assessed.
Studies
Studies on its ingredients (6)
-
Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial.
109 perimenopausal women took the rhubarb-root extract ERr 731 (sold as Estrovera/Estroven Complete) or placebo for 12 weeks. Symptoms including hot flashes improved strongly. However, most women on placebo dropped out, which makes the comparison less reliable.
- Who
- 109 perimenopausal women
- Dose
- ERr 731 one tablet/day (4 mg)
- Duration
- 12 weeks
- Result
- MRS total and each symptom improved vs placebo (P<.0001); fewer and milder hot flushes from week 4; no endometrial changes. NAMS notes only 7/55 placebo completers.
- Funding
- Authors from Health Research Services Ltd; manufacturer (Dr. Loges) funding not stated in abstract. Industry-linked
-
Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms.
A second 12-week trial by the same research group (112 women) again found large improvements with ERr 731 versus placebo. Independent replication is still lacking.
- Who
- 112 perimenopausal women
- Dose
- ERr 731 one tablet/day
- Duration
- 12 weeks
- Result
- MRS total 27.0→12.4 vs 27.0→24.0 placebo (P<.0001); hot flushes reduced.
- Funding
- Same research group as the original trial; funding not stated in abstract. Industry-linked
-
Efficacy evaluation of standardized Rheum rhaponticum root extract (ERr 731 (®)) on symptoms of menopause: A systematic review and meta-analysis study.
A pooled analysis of 4 ERr 731 studies found large symptom reductions, but the analysis was written by staff of a company that sells the extract.
- Who
- 4 studies, 390 women
- Dose
- ERr 731
- Duration
- 12 weeks
- Result
- Pooled MRS reduction -15.1 points vs control (P<.001).
- Funding
- Lead authors from Sundyota Numandis (Indian distributor) – industry-affiliated. Industry-linked
-
Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer.
In German medical records, women prescribed ERr 731 were not more likely to be diagnosed with breast cancer than women who were not. This is observational, partly industry-linked data.
- Who
- 5,686 users vs 17,058 non-users (German records)
- Dose
- ERr 731 prescriptions
- Duration
- observational
- Result
- No increase in breast-cancer diagnosis (OR 1.01, 95% CI 0.81–1.26).
- Funding
- Two authors employed by Health Research Services GmbH. Industry-linked
-
The Effects of a Saffron Extract (affron®) on Menopausal Symptoms in Women during Perimenopause: A Randomised, Double-Blind, Placebo-Controlled Study.
86 Australian women in perimenopause took saffron extract or placebo for 12 weeks. Mood and anxiety improved more with saffron, but hot flashes did not. The saffron supplier funded the study.
- Who
- 86 perimenopausal women
- Dose
- saffron extract (affron) 14 mg twice daily
- Duration
- 12 weeks
- Result
- Improved psychological symptoms (anxiety -33%, depression -32%) vs placebo; no effect on hot flashes.
- Funding
- Funded by Pharmactive Biotech (affron maker). Industry-linked
-
Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial.
60 Iranian women with depression and hot flashes took saffron (30 mg a day) or placebo for 6 weeks; both mood and hot-flash bother improved more with saffron. Small and short.
- Who
- 60 postmenopausal women with depression and hot flashes
- Dose
- saffron 15 mg twice daily
- Duration
- 6 weeks
- Result
- Hot-flash interference and depression scores improved vs placebo.
- Funding
- Academic (Iran). Independent / academic
The Menopause Society's 2023 statement is in the study library.
Price
| Regular one-time price | $19.99 (30 units, 30 days at label dose) |
|---|---|
| Cost per day | $0.67 |
| Subscription | Amazon S&S $15.65 |
| Price notes | No DTC; Amazon list $19.99 (B0DX84QTPP, now $16.47); Walmart $19.97; drugstores much higher (CVS $41.79, Walgreens $34.99–41.99) |
| In stock when checked | Yes |
| Checked | Nov 19, 2026 |
Ratings
Amazon: ★ 4.3 from 391 ratings on Amazon (checked Nov 19, 2026)
Star ratings reflect buyer satisfaction, not clinical effect.
Certifications and claims
Verified in a public registry
- No registry listing found.
Claims made by the brand
- “vegan” Brand claim
- “non-GMO” Brand claim
- “no added hormones” Brand claim
- “no soy/gluten/dairy” Brand claim
Registry check: NSF/ANSI 173 ('Nature's Bounty'): not found
Who's behind it
| Brand | Nature's Bounty |
|---|---|
| Owner / company | Nestlé Health Science (naturesbounty.com footer). |
| Founders | Not stated on the pages we read. |
| Where it's made | Made in the USA (iHerb listing). |
| Medical advisors named | None named on the pages we read. |
| Source | naturesbounty.com |
Flags & safety
Legal, regulatory and quality flags
No lawsuits, regulator actions or watchdog complaints found in our search for this product or brand.
Ingredient safety notes
- ERr 731 rhapontic rhubarb: Post-marketing (Germany, ~140M daily doses): mainly hypersensitivity and GI complaints. Observational German data: no increase in breast-cancer diagnosis (OR 1.01, industry-linked). Endometrium unchanged in trials. Contains ER-β–active compounds.
- Saffron (affron): Well tolerated at 28–30 mg/day.
Sources
Talk to a clinician first
The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).
If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.